STEM FROM NATURE,
BRANCH TO HOPE.

ABOUT AMELIO BIOMEDICAL

We are committed to develop safe and effective amino acid-based medicines.

Amelio Biomedical is committed to develop safe and effective anticancer drug with amino acids. Based on the excellent biocompatibility and safe biodegradability of amino acids, we are dedicated to conquer cancer in a safe and healthy way.

Our mission is to build a green and innovative drug development platform that improves human health. Through our research and development efforts, we aim to harness the power of amino acids to create innovative anticancer drugs that are both safe and effective.

RESEARCH AND DEVELOPMENT

USE AMINO ACID TO CURE CANCER

Amino acids are essential nutrients for all living cells, including cancer cells. Due to the characteristics of rapid growth and replication of cancer cells, the demand for amino acids is higher than that of normal cells.

Instead of starving cancer cells with anticancer drugs that block their source of nutrition, we use the opposite approach. We leverage the amino acid requirements of cancer cells and apply the AACS system to create novel anticancer molecules. With the amino acid backbone, the molecule can be taken up into cells via amino acid transporters, ultimately leading to cancer cell death via apoptosis.

OUR SCIENCE

Amino Acid Click Synthesis

We have created a new type of click chemistry. AACS is a unique and powerful atom-economy system, which conjugates amino acids and target molecules as easily as building toy blocks.

AACS can be applied in several fields, including making small molecules that can kill cancer cells without harming healthy cells, delivering drugs through amino acid carriers, and making various health supplements.

Based on this system, we have developed the mass production process of seven new molecules and previously found that two out of seven have anticancer effects.

Cancer cells has a characteristic “nitrogen trap” demanding high nitrogen content from diet and host protein. Utilizing the preference of cancer cells to absorb amino acids as a nitrogen source, the drug molecules are combined with amino acids to facilitate the entry of drugs into cancer cells. According to the Trojan Horse mechanism, we developed the first amino acid-based drug “AMBG1” by AACS system.

The unique amino acid backbone produced with AACS, may be taken up into cells via amino acid transporters.

Amino Acid Backbone Design

The characteristic “nitrogen trap” found in cancer cells describes their high demand for nitrogen and ability to assimilate nitrogen from the diet and host protein. We leverage the preference of cancer cells to absorb amino acids as a nitrogen source and combine drug molecules with amino acids to facilitate their entry into cancer cells. Using the Trojan Horse mechanism, we successfully developed the first amino acid-based drug, “AMBG1”, using the AACS system.

Due to the amino acid backbone, AACS-produced molecules can be taken up into cells via amino acid transporters.

Advantage of the AACS in Manufacturing Process

One-Pot Synthesis

High Purity with No By-product

Significantly Shorten the Manufacturing Process

OUR PRODUCT

A NOVEL AMINO ACID BASED G4 LIGAND- AMBG1

Taking advantage of cancer cells' high demand for amino acids, which have high bioavailability and safety, we developed the first amino acid-based drug “AMBG1” using the Amino Acid Click Synthesis (AACS) system. Surprisingly, preliminary findings showed that AMBG1 demonstrated a significant anticancer effect across a range of cancer types and restored normal cellular morphology and gene expression in animal models.

The “nitrogen trap” characteristic of cancer cells describes their high demand for nitrogen, which they acquire from diet and host protein. Leveraging this high demand for amino acids as a nitrogen source, we combined drug molecules with amino acids to facilitate their entry into cancer cells.

AMBG1 not only has excellent anticancer effects but also showed no hepatotoxicity or embryo toxicity. Our investigation also revealed another extraordinary phenomenon of AMBG1 as a G4 ligand. AMBG1 can bind to the G-quadruplex DNA located on the oncogene, inducing changes in gene expression that lead to cancer cell apoptosis.

FIND THE SAFER TARGET : G-QUADRUPLEX AND CANCER THERAPY

Cancer poses the greatest threat to human health and is a significant societal challenge.

G-quadruplex (G4) is a unique four-stranded structure that forms in single-stranded DNA or RNA sequences, often rich in guanine (G).

G4 plays an important role in cancer, appearing frequently in cancer-related gene regions and affecting the transcription and regulation of cancer genes.

Anticancer therapy aims to find safe and innovative molecules with high specificity and low toxicity. G4, a four-stranded secondary structure rich in guanine, plays a crucial role in cancer-related genes. Therefore, researchers use G4 as a target to develop G4-specific binding (G4 ligand), which holds great promise for the future of anticancer therapy.

G4-ligand

By binding to the G-quadruplex DNA present on the oncogene, AMBG1 induces changes in gene expression that trigger apoptosis in cancer cells.

Specificity

G4 structures are commonly found in the promoters and 5’-UTRs of highly active genes associated with cancer cells, but are not typically present in normal cells. This is why AMBG1, which targets G4 structures, exhibits a broad-spectrum anticancer effect, restoring normal gene expression and cell architecture in animal models.

Safety

AMBG1 is composed of amino acids, which are natural and safe with high bioavailability, making them ideal carriers for pharmaceutical or oncology research. In addition, experiments have shown that AMBG1 does not have hepatotoxicity or embryotoxicity, further highlighting its safety and potential as an anticancer treatment.

The Future and Application of AACS System

CONTACT US

4F.-3, No. 29-1, Ln. 169, Kangning St., Xizhi Dist., New Taipei City , Taiwan

+886-2-26955297